| Allos Therapeutics' FOLOTYN(TM) Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant |
-- New Analysis of Pivotal PROPEL Trial Presented at 51st ASH Annual Meeting -- Among the 109 patients in the PROPEL trial evaluable for response, 18 (17%) had received autologous SCT previously, including 8 (7%) who underwent autologous SCT as the most recent therapy prior to study enrollment. Sixty-three percent (5/8) of patients who received autologous SCT as their most recent therapy responded to treatment with FOLOTYN, including two complete responses (CRs). In patients who underwent autologous SCT at any time prior to treatment with FOLOTYN, an overall response rate (ORR) of 33% (6/18) was observed, suggesting single agent FOLOTYN can be an effective therapeutic option for patients who have progressed after being exposed to an intense transplant regimen. Importantly, the ORR to FOLOTYN for patients who had progressed after prior SCT was comparable to that of the ORR of 29% (32/109) observed in the overall PROPEL population. Additionally, the data demonstrated that promising results were observed in patients who responded to treatment with FOLOTYN and proceeded to receive SCT as initial subsequent therapy. Of the 109 patients evaluable for response, 6 proceeded to SCT after responding to FOLOTYN. Four of the 6 patients had responded according to independent central review and 2 of the 6 patients had responded according to investigator assessment. Thus, responses to FOLOTYN permitted patients to proceed to a potential curative transplant option.
“Stem cell transplant may be offered with curative intent in patients
with PTCL,” said About PROPEL The open-label, single-arm, multicenter, international Phase 2 clinical trial is the largest prospective study of its type ever conducted in patients with relapsed or refractory PTCL. PROPEL enrolled 115 patients with relapsed or refractory PTCL, 109 of whom were considered evaluable for efficacy according to the trial protocol. Patients were considered evaluable if they received at least one dose of FOLOTYN, their diagnosis of PTCL was confirmed by independent pathology review, and they had relapsed or refractory disease after at least one prior treatment. Patients were treated with FOLOTYN at 30 mg/m2 once weekly by IV push over 3-5 minutes for 6 weeks in 7-week cycles until disease progression or unacceptable toxicity. In addition, patients received 1mg of vitamin B12 intramuscularly every 8-10 weeks and 1.0-1.25 mg of folic acid orally on a daily basis. The primary efficacy endpoint was overall response rate (complete response, complete response unconfirmed and partial response) as assessed by International Workshop Criteria (IWC). The key secondary efficacy endpoint was duration of response. Response assessments were scheduled at the end of cycle 1 and then every other cycle (every 14 weeks). Duration of response was measured from the first day of documented response to disease progression or death. Response and disease progression were evaluated by independent central review using the IWC. Important Safety Information Warnings and Precautions: FOLOTYN may suppress bone marrow function, manifested by thrombocytopenia, neutropenia, and anemia. Monitor blood counts and omit or modify dose for hematologic toxicities. Mucositis may occur. If ≥ Grade 2 mucositis is observed, omit or modify dose. Patients should be instructed to take folic acid (1.0 -1.25 mg orally on a daily basis) and receive vitamin B12 (1 mg intramuscularly every 8-10 weeks) to potentially reduce treatment-related hematological toxicity and mucositis. FOLOTYN can cause fetal harm. Women should avoid becoming pregnant while being treated with FOLOTYN, and pregnant women should be informed of the potential harm to the fetus. Use caution and monitor patients when administering FOLOTYN to patients with moderate to severe renal function impairment. Elevated liver function test abnormalities may occur and require monitoring. If liver function test abnormalities are ≥ Grade 3, omit or modify dose. Adverse Reactions: The most common adverse reactions observed in PROPEL were mucositis (70%), thrombocytopenia (41%), nausea (40%), and fatigue (36%). The most common serious adverse events (>3%), regardless of causality, were pyrexia, mucositis, sepsis, febrile neutropenia, dehydration, dyspnea and thrombocytopenia. Forty-four percent of patients experienced a serious adverse event while on study or within 30 days after their last dose of FOLOTYN. Twenty-three percent of patients discontinued treatment due to adverse reactions. Drug Interactions: Co-administration of drugs subject to renal clearance (e.g., probenecid, NSAIDs, and trimethoprim/sulfamethaxazole) may result in delayed renal clearance. Use in Specific Patient Population: Nursing mothers should be advised to discontinue nursing or the drug, taking into consideration the importance of the drug to the mother. For additional important safety information, please see the full prescribing information for FOLOTYN at www.allos.com. About Peripheral T-cell Lymphoma
Peripheral T-cell lymphomas (PTCL) are a diverse group of aggressive
T-cell and natural killer (NK)-cell non-Hodgkin’s lymphomas (NHL) that
account for approximately 10% to 15% of all newly diagnosed cases of NHL
in
About
Safe Harbor Statement
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements include
statements regarding the potential for FOLOTYN to play an important role
for PTCL patients who have progressed after prior autologous stem cell
transplant or as a bridge to stem cell transplant for patients who
respond to FOLOTYN therapy; and other statements that are other than
statements of historical facts. In some cases, you can identify
forward-looking statements by terminology such as “may,” “will,”
“should,” “expects,” “intends,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “projects,” “potential,” “continue,” and other
similar terminology or the negative of these terms, but their absence
does not mean that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties that may cause actual results to
differ materially from those anticipated by the forward-looking
statements. Important factors that may cause actual results to differ
materially include, but are not limited to, the risks and uncertainties
associated with developing adequate sales, marketing and distribution
capabilities; the acceptance of FOLOTYN in the marketplace; the status
of reimbursement from third party payers; the Company’s dependence on
third party manufacturers; the Company’s compliance with applicable
regulatory requirements, including the healthcare fraud and abuse laws
and the Company’s post-marketing requirements; and the Company’s access
to capital to support its future operations, including product
development and commercialization plans for FOLOTYN. Additional
information concerning these and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors" section of
the Company's Quarterly Report on Form 10-Q for the quarter ended
Note: The Allos logo and FOLOTYN name are trademarks of References:
Source:
Allos Therapeutics, Inc. |
|